{"brief_title": "Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy", "brief_summary": "This is a study with two treatment sequences and two treatment periods that will assess the safety and efficacy of exenatide treatment in patients with type 2 diabetes who have inadequate glycemic control using metformin or sulfonylurea and for whom insulin is the next appropriate step in diabetes treatment.", "condition": "Type 2 Diabetes Mellitus", "intervention_type": "Drug", "intervention_name": "insulin glargine/exenatide", "description": "Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks", "arm_group_label": "Insulin glargine/exenatide", "other_name": "synthetic exenden-4", "criteria": "Main Inclusion Criteria: - Treated with a stable dose of metformin or sulfonylurea for at least 3 months prior to screening. - HbA1c between 7.1% and 11.0%, inclusive. - Insulin therapy should be the next appropriate step of diabetes treatment. - Body Mass Index (BMI) >25 kg/m2 and <40 kg/m2. Main Exclusion Criteria: - Patient previously in a study involving exenatide or glucagon-like peptide-1 analogs. - Treated with insulin, thiazolidinediones, alpha-glucosidase inhibitors, or meglitinides within 3 months prior to screening.", "gender": "All", "minimum_age": "30 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00099619.xml"}